ejpmr, 2023, 10(6), 190-199

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

ADVANCES IN THE DEVELOPMENT OF VACCINE AGAINST DIFFERENT SARS CoV-2 VARIANTS

Shivangi Saxena*, [1]Srishti Katiyar, [2]Abhay Kumar, [3]Archan Gupta, [4]Shalini Yadav and [5]Pushpendra Kumar

*Department of Pharmacology, Naraina Vidyapeeth Group of Institutions, Faculty of Pharmacy, Kanpur.
[1]Department of Pharmaceutical Chemistry, Kanpur Institute of Technology & Pharmacy, Kanpur.
[2]Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, DPSRU, New Delhi.
[3]Department of Pharmacology, Chhatrapati Shahu Ji Maharaj University, Kanpur.
[4]Department of Pharmacology, Naraina Vidyapeeth Group of Institutions, Faculty of Pharmacy, Kanpur.
[5]Department of Pharmaceutical Sciences, Radharaman Institute of Pharmaceutical Sciences, Ratibad, Bhopal MP.

***Corresponding Author: Shivangi Saxena**

Department of Pharmacology, Naraina Vidyapeeth Group of Institutions, Faculty of Pharmacy, Kanpur.

Article Received on 07/04/2023 **Article Revised on 28/04/2023** **Article Accepted on 18/05/2023**

ABSTRACT

The coronavirus 2 that causes the severe acute respiratory syndrome, a worldwide disease that has caused devastation on public health, human lives, and the global economy. Vaccination is regarded as one of the most significant breakthroughs during medical history. Based on past SARS-CoV vaccine development experience, All COVID-19 vaccinations should be investigated for both protective advantages and potential risks eosinophilic infiltration and/or increased infectivity may come from antibody-dependent enhancement. This is regarded as the world leader in SARS-CoV-2 vaccine research, the Sinopharm CNBG initiating the most current international clinical investigation in the UAE. We discuss recent developments in vaccine research against SARS-CoV-2 clinically relevant strains, such initiatives, it is predicted, would contribute in the developments of effective and economical SARS-CoV-2 vaccine.

KEYWORDS:

INTRODUCTION

A peculiar pneumonia outbreak was reported in late Dec 2019 in the China city of Wuhan province of Hubei. Six months later, with more than ten million cases, the coronavirus disease 2019 pandemic has become the twentieth century's largest public health crisis.[1] A betacoronavirus causes SARS-CoV-2, which SARS-CoV and is closely linked. June 28, 2022, 06:54, 549893671 coronavirus cases and 525762095 coronavirus cases cured, 6352343 people died due to coronavirus COVID-19 outbreak. The impending coronavirus pneumonia pandemic has been termed PHEIC by the WHO.[2]

The whole world should rapidly isolate the transmission channel and implement strong methods of preventive and control. In 2002-2003, the world witnessed the first in a series of deadly coronavirus pandemics.[3] severe acute respiratory syndrome first appeared in southern China and quickly spread to neighboring countries, resulting in 8096 cases and 774 deaths in 26 countries.[4] Despite scientific efforts, no commercial vaccine is available, and Since 2004 no cases of SARS have been reported. Then, in September 2012, a different coronavirus outbreak known as MERS emerged.[5] While moderate respiratory symptoms were typical of infectious Saudi Arabian illness symptoms, MERS The symptoms often lead to ARDS and death. Although there have been cases of MERS since 2015, there is insufficient data to declare it a pandemic.[6]

There is no licensed vaccination for MERS, as there is for SARS. There are many reasons for the inability to make SARS and MERS vaccine. Pre-clinical vaccination research on MERS was delayed due to the lack of adequate and cost-effective small animal models. Furthermore, because the incidence of MERS has been intermittent and geographically limited, there has been less emphasis on the development of MERS vaccines.[7] Investing in the development of SARS vaccines is difficult because the disease has not been documented since 2014, meaning SARS-CoV has disappeared. COVID-19 symptom induced the symptoms of SARS-CoV-2 are often minor, such as fever, cough and shortness of breath.[8] However, a number of severe symptom, including the symptoms of SARS-CoV-2 are often minor, such as fever, can occur in older individuals and people with chronic conditions.[9] Although there is currently no vaccine available for SARS or MERS,

earlier and continued efforts to develop vaccine for such disease could be key in the development of an effective SARS-CoV-2 vaccines. SARSCoV-2 is a single strand Ribonucleic acid virus with a positive sense.[10]

VACCINES OF CORONAVIRUS (SARS & MERS)

After the outbreak of SARS in 2002–2003, many laboratories around the world began to search for vaccinations because of the sickness.[11] The viral S glycoprotein has been used in the majority of subunit vaccinations, which served as a vehicle for viral entry.[12] Consequently, vaccination with the vaccine can elicit A big impact in blocking this protein is having strong immunological reactions to it viral spontaneous infection penetration into host cells. For pre-clinical studies, all vaccine forms were evaluated. To create live-attenuated and inactivated viral vaccines, whole SARS-CoV was used.[13]



Fig. no1 SARS CoV 2 STRUCTURE.



Fig No. 2 The MERS-CoV S glycoprotein binds to the viral envelop.

The Phase I clinical studies have already started with SARS virus vaccines that have been inactivated, DNA vaccines, and SARS S glycoprotein subunit vaccines.[14] Phase I clinical studies have begun for SARS viral vaccines that have been inactivated, DNA vaccines, and SARS vaccinations S glycoprotein subunit vaccination.[15] This is usually done by infecting vaccinated animals and humans with the infectious virus. Because of SARSCoV, no human challenge trials were conducted, and therefore the vaccinations' safety and effectiveness were not studied or validated.[16]

Because of SARSCoV, no human challenge trials were conducted, and therefore the vaccinations' safety and efficacy were not examined as well as confirmed. Like the SARS vaccination, The S glycoprotein is used in the majority of MERS vaccinations. Animal models were used to develop and test Virus vaccines that have been inactivated, live virus vaccines that have been attenuated.[17] A DNA-based vaccination has been researched, while vaccines based on MVA and adenovirus are still in phase I clinical trials.[18]

VACCINES OF CORONAVIRUS (SARS-CoV-2)

Human-use vaccinations would take years, if not decades millions of dollar to create, especially if new technology are introduced were used that were not properly evaluated or increased in size for mass manufacture.[19] due to There are no commercially available coronavirus vaccines and no significant production capability, such methods and technology will have to be created.[20] They can be complicated, delicate. The alliance has provided funding for pandemic preparedness innovation to a number of New Sophisticated Players (CEPIs) in the sector.[21] The majority of them are expected to be successful in the development of SARS-CoV-2 vaccines.[22]

Nonetheless, neither of these institutions or businesses currently have a route to enter the regulatory investigations for such a vaccine in late-stage clinical authorities bodies can authorize.[23] They are now unable to provide the required amount of dosage. Following infusion, an mRNA-based vaccination in vivo expression of a target antigen encapsulated in lipid nanoparticles.[24] Several vaccines are currently in the pre-clinical stage. Because each of these tactics has benefits and drawbacks.[25]

Adenovirus-based vector vaccination has been tested employed that has not yet been licensed as a vaccine. Because the production technology for the The SARS-CoV-2 vaccine is comparable to the Flublok approved recombinant influenza virus vaccine, the vaccine might be ready for human usage in a matter of months or years.[26] As a modified vaccination candidate, a pilot-scale production technology was created for an SARS-CoV-2 viral vaccine inactivated. In mice, the PiCoVacc vaccination stimulated the development of SARS-CoV-2 specific neutralising anti-body, Rat and rhesus monkey were used to successfully neutralise 10 typical SARS-CoV-2 strains.[27] There was a partial protective impact with 3 g of vaccine and a full protective response with 6 g of vaccine when rhesus monkeys were vaccinated with PiCoVacc vaccine at two different doses (3 g or 6 g per monkey).[28] There was also no increase in Infection caused by antibodies or immunopathological degeneration. The PiCoVacc vaccine was thoroughly tested in rhesus monkeys, monitoring histopathology, blood biochemistry, and clinical signs. PiCoVacc vaccination was shown to be harmless and well-tolerated. According to the results of the experiments, the PiCoVacc vaccines is anticipated to have a spectrum neutralising effects on SARSCoV-2 outbreaks worldwide.[29] According to preliminary studies, adverse effects related to mRNA-1273 immunisation in a limited number of older adults were primarily mild to moderate. This population is highly vulnerable to COVID-19 illness and mortality. The binding and neutralising antibody titers were greater in the 100 g dosage than in the 25 g dose, suggesting that the dosage of 100 g level and two-dose protocol should be studied further. More variety the safety and efficacy of mRNA-1273 immunisation will be evaluated in phase 3 population-based studies, as well as to quantify protection against COVID-19. This information will pave the way for accelerated Human SARS-CoV-2 vaccine clinical developments.[30]

During the COVID-19 pandemic, one problem arose in which many nations, several countries are leading the rush to produce SARS-CoV-2 vaccines is on. Countries such as the US and Russian, on the other hand, supply large quantities of COVID-19 vaccine dose to their residents and favor their market over many other countries that provide them.[31] This is called "vaccine nationalism". Pre-purchase agreements between the vaccine manufacturer and the government can accomplish this; Nevertheless, The world health organization has warned against vaccine nationalism, arguing that It would favour the virus over humans. This is not a new concern, as a similar phenomenon was observed during the 2009 H1N1 influenza pandemic. At the time, Australia was a leader in the production of H1N1 influenza vaccines, and the government restricted export; nevertheless, affluent nations went to pre-purchase talks with several pharmaceutical companies.[25]

CREATING VACCINES THAT CHALLENGES SARS-CoV-2

Over the past decade, experience-based vaccination businesses have made significant advances in human health. However, in the context of molecular microbiology and contemporary immunology, vaccine research is still in its infancy, requiring a longer time span for developing a new vaccination. When producing new vaccines, increasing health concerns, highly advanced manufacturing techniques and related research parameters must be carefully and methodically evaluated. If a SARS-CoV-2 vaccine is produced quickly

for clinical use, the new guidelines will be needed to address challenges of significance that crosses the boundaries of medicine, technology, regulation, and public safety.[32]



Fig no. 3 Future SARS-CoV-2 vaccine development.

In recent years, the relationship between the immune response and the protective benefits of candidate vaccines has been called into persistent doubt. Structure-directed antigen production is becoming increasingly prevalent. Furthermore, vaccine development is not a well-established scientific discipline.[33] Could the protective role of antibodies to certain vaccination programs be the primary immunological response to SARS-CoV-2. Despite the inherent difficulties in properly conducting feasibility trials, constraint animal models for free will be extremely valuable for the selection of candidates for clinical trials.[34]

Currently, vaccine development necessitates a diverse collection of skills. A wide range of advancements have come to the fore during the previous two decades. In addition, the inventor could rapidly scale up his vaccine idea to produce up to 10 million doses of Good Manufacturing Practice (GMP). Those who have established facilities and manufacturing experience will be in a better position.[35] This will have an impact on vaccine preparation and immunogen selection. Will an efficient Will the production cycle be sufficient for the selected vaccines to advance, or will it need to be validated. Will knowledge gathered in other nations' manufacturing and regulatory systems be utilised to assess vaccine application in the present country. Eventually, global demands will be set to provide the world with equal access to effective SARS-CoV-2 vaccination. To accomplish full epidemic control, the following issues must be addressed: vaccine ownership, unmatched development finance, price and supply networks.[36]

VACCINATION TECHNIQUE BASED ON HOST CORONAVIRUS PATHOGENESIS

It is critical to determine if SARS-CoV-2 produces pulmonary pneumonia through viremia or after an upper respiratory infection. In the event of influenza infection, live replication vector vaccine and attenuated virus vaccine successfully generate local mucosal immunity, resulting in upper and lower respiratory tract protection and limiting runny nose.[37] Despite the fact that live attenuated influenza virus vaccinations generate largely local IgA antibodies and low.[38]

This may be compatible with the mechanism behind IM-based eradication of human respiratory diseases with passive influenza vaccination. This will strengthen tolerance and memory B- and T-cell responses while also preventing re-infection with the virus. Because diarrhea and loose stools have been observed in some SARS-CoV-2 individuals, oronasal vaccines may be more appropriate in this situation.[39] Consequently, the immunogenicity, protective efficacy and the adverse effects of potential vaccinations may differ between these categories. In each community and in different age group in Assessment of pre-existing immunity levels will be crucial in establishing vaccination efficacy and safety in each population, particularly the elderly, who have the greatest death rate.[40]

ATTEMPTS TO DEVELOP A SARS-CoV-2 VACCINE

VACCINES AGAINST THE VIRUS

Conventional manufacturing processes are used to create both live-attenuated and inactivated viral vaccine. Corporate sources claim that, Johnson & Johnson is one of the major pharmaceutical company that is preparing to make the SARS-CoV-2 vaccine.[41] He used Janssen's Advac adenoviral vector and its PER in his Ebola vaccine concept. Based on this approach, they created an Ebola vaccine using The PER.C6 cell line technology and Janssen's Advac adenoviral vector. Codagenics has created a "codon deoptimization" technology to reduce the virus and designed the SARS-CoV-2 vaccination method.[42] An important advantage is the TLRs expressed on innate immune cells, such as TLR3, TLR7/8, and TLR9, are activated by whole viral vaccinations.[43] Nonetheless, it is important to test live viruses for the sake of safety profiles and protective effects.[44]

Covaxin (also known as BBV152) is a fully inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the National Institute of Virology, Indian Council of Medical Research. As of October 2021, 110.6 million people in India had received Covaxin. On November 3, 2021, the World Health Organization (WHO) validated the vaccine for emergency use. As of January 31, 2022, Covaxin is licenced for emergency use in 13 countries.

The Covishield vaccination is designed to protect against COVID-19. One of these is the viral vector vaccine for the prevention of COVID-19. It was built in the United Kingdom by Oxford University and British-Swedish business AstraZeneca. Using modified chimp adenovirus ChAdOx1 as a vector.

Sputnik V is the world's first approved vaccine based on extensive studies in human adenovirus vector technology. It is legal in 71 countries with a total population of 4 billion. The first Soviet space satellite was named Vaccine. The launch of Sputnik-1 in 1957 reignited worldwide interest in space research, ushering in the so-called "Sputnik moment" for the international community.

VACCINE FOR SUBUNITS

The most visible target subunits in SARS-CoV and SARS-CoV-2 vaccine are the S proteins in vaccine development, which would lead to suppression of viral interacting with angiotensin-converting enzyme 2 in the host.[45] Clover Biopharmaceuticals Inc., on the other hand, is using its proprietary trimer-tag technology was used to develop a trimerized SARS-CoV-2 S-protein subunit vaccine. Full-length S-proteins, on the other hand, may cause eosinophilic infiltration and enhanced infectivity following SARS-CoV-2 infection.[46] the shot administered A significant amount of defence against the domestic virus is elicited by alum. RBD-based vaccination has the potential to reduce host immunopotentiation.[47] More than 80% of SARS-CoV and SARS-CoV-2 RBD amino acid sequences are similar, and both viruses attach to the ACE2 receptor, meaning that vaccine development techniques can used for SARS-CoV creation of vaccine.[48]

VACCINES WITH NUCLEIC ACID

Nucleic acid vaccines have been developed by many pharmaceuticals company against SARS-CoV-2. Inovio Pharmaceuticals, some examples, developed Moderna Therapeutics and Curevac are working on deoxyribonucleic acid vaccines, while Moderna Therapeutics and Curevac are working on ribonucleic acid vaccines techniques.[49] DNA vaccines were shown in 1993 to generate in mouse models, immune defences against influenza is demonstrated. However, non-clinical investigations have not been converted to clinical trials in humans. Recently, considerable progress has been made in the creation of protection-promoting nucleic acid vaccines. While currently, only animal vaccinations containing nucleic acids are utilised, it is increasingly like that they will be used in people.[50]

ANTIGENS SELECTION

WHOLE CELL ANTIGENS (WCA)

Virus elements such as other structural and non-structural elements include Included are substances like proteins, lipids, polysaccharides, nucleic acids, and others. Typical WCA vaccinations include Virus vaccines, both dead and live-attenuated.[51] given the diversity of WCA formulations, it's crucial to keep a careful eye on performance reviews and quality control. Several universities have successfully discovered SARS-CoV-2 viral strains and are working on dead or live WCA vaccines. It is important to identify strains with minimal or no pathogenicity, and rigorous screening of vaccination candidates.[52]

S PROTEIN

The most likely source of antigen for the vaccine is the S protein. For starters, surface proteins recognized by the host immune system as viral. Second, by using ACE2 as the entrance receptor, it enhances the interaction of host

cells with the virus, resulting in pathogenicity.[53] Furthermore, Vaccines against SARS-CoV and MERS-CoV have been developed using homologous proteins, both of which have been demonstrated to be effective in non-clinical testing.[54] Similarly to other first-generation membrane fusion proteins, the S protein immediately forms a homo-trimer by self-association.[55]

N PROTEIN

The N protein, which has a molecular weight of around 50 kDa, is highly conserved across CoVs.[56] this protein has been shown to be highly antigenic in 89 percent of SARS patients, eliciting antibodies to this antigen. Other studies, the another hands, discovered that N protein immunisation did not significantly boost the formation of neutralising antibodies in hamsters and did not give protection against infection.[57] These findings show that the vaccines of SARS-CoV-2 based on the N protein may be ineffective. N protein, can be used as a marker in clinical studies due to its strong immunoreactivity.[58]

M PROTEIN

The molecular weight of M protein is roughly 25 kDa, is a transmembrane glycoprotein that contributes in viral replication. The SARS-CoV surface is covered in large amounts of this protein.[59] Vaccination with In SARS patients, full-length M protein resulted in neutralising antibodies.[60] Immunogenic and structural investigations revealed that the M protein has a T-cell epitope cluster that can activate a powerful cellular immunological response. These proteins are is very conserved among viral types and may serve as a target antigen.[61]

E PROTEIN

The E protein has ion-conducting properties and is composed of 76–109 amino acids. These protein has been shown to be capable of activating the inflammasome, resulting in the generation of IL-1 and, ultimately, significant inflammatory responses.[62] The E protein is known to cause cytokine storms in SARS-CoV patients. Consequently, it can be challenging to manage immunological responses after vaccination using Vaccines based on E protein.[63] Unlike the S, N, and M proteins, the proteins is not suited in order to be used as an immunogen in vaccine production.[64]

SAFETY

It is problematic to introduce ADE and others negative consequences as a result of Biological re-exposure or vaccination.[65] ADE occurs when non-neutralizing antibodies assist viral entry into host cells, hence increasing the virus's infectiousness.[66] ADE has been documented in cats that have received a COV vaccination injection. The presence of ADE in the SARS animal model cannot be ruled out.[67] Indeed, a number of inactivated whole virus vaccines including SARS S glycoprotein vaccines have been associated with animal models of hepatitis and pulmonary immunopathology.[68] It is important to emphasize that SARS-CoV vaccinated animal are not immune to MERS-CoV infection, which can have serious consequences if secondary infection occurs.[69] Several investigations on passive antibody transmission in rats as well as research with nonhuman primates have found no indication of ADE or adverse outcomes. ADE can be prevented by employing a shortened version of the S glycoprotein.[70] According to this idea, The RBD or S1 component of the S glycoprotein is in charge of producing neutralising antibodies, whereas the S2 subunit causes non-neutralizing antibodies, resulting in ADE.[71]

PROSPECTS

The aetiology, epidemiology, functional origin, pathogenic mechanism, disease immunological response, and other characteristics of SARS-CoV-2 are poorly understood.[72] Furthermore, SARS-CoV-2 host cellular and humoral immune responses are critical for vaccine development, remain unclear. These concerns will be addressed in the near future through basic research for the successful manufacture of vaccines.[73] Several governments and research organizations have announced efforts to produce SARS-CoV-2 vaccines.[74] In general, the vaccine's safety, immunogenicity and efficacy will be evaluated over three rounds of clinicals trial.[75] Typically, it takes more than ten years to introduce a new vaccine, and more than 89 percent of proposals are rejected by regulatory authorities.[76]

In the early stages of COVID-19 at Wuhan, there were 149 mutation sites in the 103 sequenced SARS-CoV-2 genomes, and the virus proceeded in two distinct forms, termed L and S.[77] Clinical trials evaluating several drugs are now underway, with the intention of developing a new treatment to combat SARS-CoV-2-related disorders.[78] Furthermore, expediting vaccine manufacturing and administration is an effective way to end the worldwide SARS-CoV-2 pandemic. While the creation of vaccination is slow compared to the spread of the pandemic, it is still necessary.[79] First, the pandemic is still spreading globally, when more reported instances are uncovered, and the tipping point has yet to be achieved.[80]

It should be noted that SARS-CoV-2 was discovered just 6 months ago, and following research into SARS-CoV-2 pathogenic features and mechanisms has only recently begun. Consequently, because the facts and information obtained.[81]

CONSLUSION

Experience in creating vaccines for CoV strains like SARS-CoV and MERS-CoV is used to produce SARS-CoV-2 vaccines. For safety validation of SARS-CoV-2 vaccine candidates, ADE and other side events often linked with SARS and MERS vaccination candidates must be extensively addressed.

Animal studies have shown that such reactions are both durable and protective. In addition, there is evidence of human lifespan, especially over a longer period. The use

of novel adjuvants, S-glycoprotein tailoring, delivery methods, and as yet unknown vaccination technologies should be considered to promote immunoreactivity while avoiding any negative side effects. It should be noted that there are several advantages to using CoV N protein for vaccination. As stated earlier, using this antigen can lead to long-term protective immunity. Vaccination demonstrates this point is reserved for illnesses that have already been eradicated and lack naturally acquired immunity.

The introduction of SARS-CoV-2 vaccination to suppress the first wave of COVID-19 came too late. Still, they can be useful if there are frequent waves later or if this virus spreads as a seasonal virus after a pandemic. Moreover, the lessons learned from dealing with this pandemic should help us be better prepared for the future. The virus is likely to persist.

REFERENCE

1. Awadasseid A, Wu Y, Tanaka Y, Zhang W. Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China. International Journal of Biological Sciences, 2020; 16: 1846-60. http://www.ijbs.com/v16p.htm.
2. HuiDS IAE, Madani T, Ntoumi F, Koch R, Dar O. The continuing 2019-nCoV epidemicthreatof novel coronaviruses to global health: the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis., 2020; 91: 264-6.
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 2020; DOI: 10.1056/NEJMoa2001017.
4. Control ECfDPa. European Centre for Disease Prevention and Control 2020; https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.
5. [Internet] NHS. SARS (severe acute respiratory syndrome). https:// www.nhs.uk/conditions/sars/ Accessed 15 Feb 2020. 2020.
6. [Internet] WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 2003. https://www.who.int/csr/sars/country/table2004_04_21/en/ Accessed 15 Feb 2020. 2020.
7. [Internet] CDC. MERS Clinical Features, Middle East Respiratory Syndrome https://www.cdc.gov/coronavirus/mers/clinical-features.html. Accessed 15 Feb 2020. 2020.
8. [Internet] WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). 2020. https://www.who.int/emergencies/mers-cov/en/ Accessed 3 Apr 2020. 2020.
9. [Internet] WHO. Middle East respiratory syndrome coronavirus (MERS-CoV)—Republic of Korea. 2015. https://www.who.int/csr/don/25- october-2015-mers-korea/en/ Accessed 15 Feb 2020. 2020.
10. Padron-Regalado E. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains. Infectious diseases and therapy, 2020: 1-20. https:// doi.org/10.1007/s40121-020-00300-x.
11. [Internet] WHO. Q&A on coronavirus (COVID-19). 2020. [Online]. https://www.who.int/news-room/q-adetail/q-a-coronaviruses. Accessed 3 Apr 2020. 2020.
12. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research, 2020; 7: 1-10.
13. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nature reviews Microbiology, 2009; 7: 226-36.
14. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunology and cell biology, 2004; 82: 488-96.
15. Lauer KB, Borrow R, Blanchard TJ. Multivalent and multipathogen viral vector vaccines. Clin Vaccine Immunol, 2017; 24: e00298-16.
16. Urakami A, Sakurai A, Ishikawa M, Yap ML, Flores-Garcia Y, Haseda Y, et al. Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus. Clin Vaccine Immunol, 2017; 24: e00090-17.
17. Lin J, Zhang J-S, Su N, Xu J-G, Wang N, Chen J-T, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antiviral therapy, 2007; 12: 1107.
18. Zhao L, Seth A, Wibowo N, Zhao C-X, Mitter N, Yu C, et al. Nanoparticle vaccines. Vaccine, 2014; 32: 327-37.
19. Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. The Lancet Infectious Diseases, 2019; 19: 1013-22.
20. [Internet] Arabia ctsiS. N. and events University of Oxford. New MERS vaccine clinical trial starts in Saudi Arabia, 2019. https://www.ox.ac.uk/news/2019-12-19-new-mersvaccine-clinical-trial-start s-saudi-arabia. Accessed 15 Feb 2020. 2020.
21. [Internet] NIH-ClinicalTrial.gov. Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERSS. 2019. https://clinicaltrials.gov/ct2/show/ NCT03615911 outcomemeasures. Accessed 15 Feb 2020. 2020.
22. Schindewolf C, Menachery VD. Middle east respiratory syndrome vaccine candidates: cautious optimism. Viruses, 2019; 11: 74.
23. Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus research, 2014; 194: 200-10.

24. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity, 2020; https://doi.org/10.1016/j.immuni.2020.03.007.
25. Johnson Ja. What You Need to Know About the Latest on the Coronavirus— and a Potential Preventive Vaccine. https://www.jnj.com/latest-news/ what-you-need-to-know-about- coronavirus-and-a-potentialjohnson-johnsonvaccine. 2020.
26. Sanofi. Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine. http://www.news.sanofi. us/2020-02-18-Sanofi-joins-forces- with-U-S-Department-of-Health-and-Huma n-Services-to-advance-a-novel-coronavirus- vaccine. 2020.
27. Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M, et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine, 2006; 24: 3624-31.
28. Gao Q, Bao L, Mao H, Wang L, Xu K, Li Y, et al. Rapid development of an inactivated vaccine for SARS-CoV-2. bioRxiv. 2020; doi: https://doi.org/ 10.1101/2020.04.17.046375.
29. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine. 2020:. DOI: 10.1056/NEJMoa2028436.
30. Kumar P, Sah AK, Tripathi G, Kashyap A, Tripathi A, Rao R, et al. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Molecular and Cellular Biochemistry, 2020: 1-22. https://doi.org/10.1007/s11010-020-03924-2.
31. Lu S. Timely development of vaccines against SARS-CoV-2. Emerging Microbes & Infections, 2020; 9: 542-4.
32. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. New England Journal of Medicine, 2012; 366: 1275-86.
33. Lu S. Editorial overview: vaccines against challenging viral pathogens and new vaccine technology. DOI: 10.1016/j.coviro.2014.04.006. 2014.
34. Saif LJ. Vaccines for COVID-19: perspectives, prospects, and challenges based on candidate SARS, MERS, and animal coronavirus vaccines. Euro Med J., 2020; DOI/10.33590/ emj/200324.
35. Rudraraju R, Mordant F, Subbarao K. How live attenuated vaccines can inform the development of broadly cross-protective influenza vaccines. The Journal of infectious diseases, 2019; 219: S81-S7.
36. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virologicalassessment of hospitalized patients with COVID-2019. Nature, 2020: 1-5. https://doi.org/10.1038/s41586-020-2196-x.
37. J&J. working on coronavirus vaccine. thepharmaletter 2020. https://www. thepharmaletter.com/article/j-j-working-on-coronavirusvaccine. Accessed 28 Feb 2020. 2020.
38. ClinicalTrials.gov. National Institutes of Health. https://clinicaltrials. gov/ct2/show/NCT02543567. Accessed February 7, 2020. 2020.
39. E. C. China coronavirus: Hong Kong researchers have already developed vaccine but need time to test it, expert reveals. South China Morning Post. https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hongkong-researchers-have. Accessed 28 Feb 2020.
40. J. S. Codagenix raises $20 million for a new flu vaccine and other therapies. Tech Crunch. https://techcrunch.com/2020/01/13/codagenix-raises-20-million-for-a-new-flu-vaccine-and-othertherapies/. Accessed 28 Feb 2020.
41. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng C-TK, Curti E, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert review of vaccines, 2012; 11: 1405-13.
42. Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine, 2014; 32: 3169-74.
43. Pipelinereview.com. Clover Biopharmaceuticals. Clover initiates development of recombinant subunit-trimer vaccine for Wuhan coronavirus (2019-nCoV). 2020. https://pipelinereview.com/index.php/2020012873644/Vaccines/Clover-Initiates Development-of-Recombinant-Subunit-Trimer-Vaccine-for-Wuhan-Coronavirus-2019nCoV.html. 2020.
44. Chen W-H, Chag SM, Poongavanam MV, Biter AB, Ewere EA, Rezende W, et al. Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate. Journal of pharmaceutical sciences, 2017; 106: 1961-70.
45. Chen W-H, Du L, Chag SM, Ma C, Tricoche N, Tao X, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Human vaccines & immunotherapeutics, 2014; 10: 648-58.
46. Chen W-H, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. Current tropical medicine reports, 2020: 1-4. https://doi.org/10.1007/s40475-020-00201-6.
47. Barteling S. Development and performance of inactivated vaccines against foot and mouth disease. Revue scientifique et technique-Office international des epizooties, 2002; 21: 577-83.

48. Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology, 2015; 479: 379-92.
49. Marohn ME, Barry EM. Live attenuated tularemia vaccines: recent developments and future goals. Vaccine, 2013; 31: 3485-91.
50. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020; 367: 1260-3.
51. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 2020: 1-6.
52. Zhou Y, Jiang S, Du L. Prospects for a MERS-CoV spike vaccine. Expert review of vaccines, 2018; 17: 677-86.
53. Zakhartchouk AN, Sharon C, Satkunarajah M, Auperin T, Viswanathan S, Mutwiri G, et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine, 2007; 25: 136-43.
54. Woo PC, Lau SK, Tsoi H-w, Chen Z-w, Wong BH, Zhang L, et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine, 2005; 23: 4959-68.
55. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, et al. Receptor-binding domain of SARS- CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochemical and biophysical research communications, 2004; 324: 773-81.
56. Li F. Structure, function, and evolution of coronavirus spike proteins. Annual review of virology, 2016; 3: 237-61.
57. McBride R, Van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses, 2014; 6: 2991-3018.
58. Leung DTM, Chi Hang TF, Chun Hung M, Sheung Chan PK, Cheung JLK, Niu H, et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets them viral nucleocapsid. The Journal of infectious diseases, 2004; 190: 379-86.
59. Kim TW, Lee JH, Hung C-F, Peng S, Roden R, Wang M-C, et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. Journal of virology, 2004; 78: 4638-45.
60. Collisson EW, Pei J, Dzielawa J, Seo SH. Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Developmental & amp; Comparative Immunology, 2000; 24: 187-200.
61. Seo SH, Pei J, Briles WE, Dzielawa J, Collisson EW. Adoptive transfer of infectious bronchitis virus primed αβ T cells bearing CD8 antigen protects chicks from acute infection. Virology, 2000; 269: 183-9.
62. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proceedings of the National Academy of Sciences, 2004; 101: 9804-9.
63. Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, et al. A structural analysis of M protein in coronavirus assembly and morphology. Journal of structural biology, 2011; 174: 11-22.
64. Pang H, Liu Y, Han X, Xu Y, Jiang F, Wu D, et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. Journal of general virology, 2004; 85: 3109-13.
65. Liu J, Sun Y, Qi J, Chu F, Wu H, Gao F, et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. The Journal of infectious diseases, 2010; 202: 1171-80.
66. Nieto-Torres JL, DeDiego ML, Verdia-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA, Fernandez-Delgado R, et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS pathogens, 2014; 10.
67. Dimmock K EN, Leppard AJ. Introduction to modern virology. In: Malden MA, editor. Introduction to modern virology. New York: Blackwell Pub, 2007; 65: 2007.
68. Vennema H, De Groot R, Harbour D, Dalderup M, Gruffydd-Jones T, Horzinek M, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. Journal of virology, 1990; 64: 1407-9.
69. Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one, 2012; 7.
70. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double- inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. Journal of virology, 2011; 85: 12201-15.
71. Czub M, Weingartl H, Czub S, He R, Cao J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine, 2005; 23: 2273-9.
72. Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is

associated with enhanced hepatitis in ferrets. Journal of virology, 2004; 78: 12672-6.
73. Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng B-H, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Human vaccines & immunotherapeutics, 2016; 12: 2351-6.
74. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proceedings of the National Academy of Sciences, 2014; 111: 4970-5.
75. Houser KV, Broadbent AJ, Gretebeck L, Vogel L, Lamirande EW, Sutton T, et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS pathogens, 2017; 13: e1006565.
76. Luo F, Liao F-L, Wang H, Tang H-B, Yang Z-Q, Hou W. Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine. Virologica Sinica, 2018; 33: 201-4.
77. Stadler K, Roberts A, Becker S, Vogel L, Eickmann M, Kolesnikova L, et al. SARS vaccine protective in mice. Emerging infectious diseases, 2005; 11: 1312.
78. Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. The Lancet, 2004; 363: 2122-7.
79. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proceedings of the National Academy of Sciences, 2004; 101: 6641-6.
80. Kong W-p, Xu L, Stadler K, Ulmer JB, Abrignani S, Rappuoli R, et al. Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. Journal of virology, 2005; 79: 13915-23.
81. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas Jr WD, Coccia JA, et al. b Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice. The Journal of infectious diseases, 2005; 191: 507-14.